Taltz (ixekizumab) vs Skyrizi (risankizumab)
Taltz (ixekizumab) vs Skyrizi (risankizumab)
Taltz (ixekizumab) and Skyrizi (risankizumab) are both injectable biologic medications used to treat moderate to severe plaque psoriasis, among other conditions. Taltz works by targeting interleukin-17A (IL-17A), a protein that plays a role in inflammation, while Skyrizi targets interleukin-23 (IL-23), another key protein in the inflammatory process associated with psoriasis. The choice between Taltz and Skyrizi may depend on individual patient factors, including response to treatment, medical history, potential side effects, and the specific recommendations of a healthcare provider.
Difference between Taltz and Skyrizi
Metric | Taltz (ixekizumab) | Skyrizi (risankizumab) |
---|---|---|
Generic name | Ixekizumab | Risankizumab |
Indications | Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis | Plaque psoriasis, Psoriatic arthritis |
Mechanism of action | Interleukin-17A antagonist | Interleukin-23 antagonist |
Brand names | Taltz | Skyrizi |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Injection site reactions, Upper respiratory infections, Nausea, Fungal infections | Upper respiratory infections, Headache, Fatigue, Injection site reactions |
Contraindications | Hypersensitivity to ixekizumab or any of the excipients | Hypersensitivity to risankizumab or any of the excipients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Eli Lilly and Company | AbbVie Inc. |
Efficacy
Efficacy of Taltz (Ixekizumab) in Treating Psoriasis
Taltz (ixekizumab) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Ixekizumab works by targeting interleukin-17A (IL-17A), a cytokine that plays a key role in the pathogenesis of psoriasis. Clinical trials have demonstrated that Taltz can lead to significant skin clearance in many patients. For instance, in the UNCOVER clinical trial series, a majority of patients treated with Taltz achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score, and many achieved a 90% reduction (PASI 90) or even complete clearance (PASI 100) within 12 weeks of treatment.
Efficacy of Skyrizi (Risankizumab) in Treating Psoriasis
Skyrizi (risankizumab) is another biologic medication approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Risankizumab targets the interleukin-23 (IL-23) cytokine, which is also implicated in the development of psoriasis. Skyrizi has shown high levels of efficacy in clinical trials. The UltIMMa-1 and UltIMMa-2 phase 3 trials reported that more than 75% of patients achieved PASI 90 by week 16, and over half of the patients reached PASI 100. These results indicate that Skyrizi can produce profound skin clearance in a significant proportion of patients with psoriasis.
Comparison of Efficacy Between Taltz and Skyrizi
When comparing the efficacy of Taltz and Skyrizi, both medications have shown high efficacy rates in their respective clinical trials. However, direct comparisons are challenging without head-to-head trials. The choice between Taltz and Skyrizi may be influenced by various factors, including individual patient response, specific clinical scenarios, and the safety profiles of the medications. Physicians typically make treatment decisions based on a combination of these factors, along with patient preference and insurance coverage.
Conclusion on the Efficacy of Taltz and Skyrizi for Psoriasis
In conclusion, both Taltz (ixekizumab) and Skyrizi (risankizumab) are highly effective treatments for moderate to severe plaque psoriasis, with a significant number of patients achieving substantial or complete skin clearance. While both target different cytokines involved in the pathogenesis of psoriasis, they represent important options in the management of this chronic skin condition. Ongoing research and post-marketing surveillance continue to provide valuable information about the long-term efficacy and safety of these medications for individuals living with psoriasis.
Regulatory Agency Approvals
Taltz
Skyrizi
Access Taltz or Skyrizi today
If Taltz or Skyrizi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us